---
title: "SGHT: Q2 revenue up 20% YoY, guidance raised, and strong growth in both glaucoma and dry eye segments"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295022666.md"
description: "Q2 2026 saw 20% revenue growth, record performance in both interventional segments, and improved margins. Full-year guidance was raised, cash usage dropped, and new product launches and payer wins support continued momentum.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-05T22:05:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295022666.md)
  - [en](https://longbridge.com/en/news/295022666.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295022666.md)
generator: "portal-rs"
---

# SGHT: Q2 revenue up 20% YoY, guidance raised, and strong growth in both glaucoma and dry eye segments

Q2 2026 saw 20% revenue growth, record performance in both interventional segments, and improved margins. Full-year guidance was raised, cash usage dropped, and new product launches and payer wins support continued momentum.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [SGHT.US](https://longbridge.com/en/quote/SGHT.US.md)

## Related News & Research

- [Sight Sciences Q2 revenue rises 20%, beats estimates](https://longbridge.com/en/news/295013505.md)
- [Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System | SGHT Stock News](https://longbridge.com/en/news/294876777.md)
- [AI Was Supposed to Kill Wix. Google Just Gave It a Way to Fight Back.](https://longbridge.com/en/news/297433684.md)
- [Stocks in Play: Bausch + Lomb Corporation](https://longbridge.com/en/news/297663193.md)
- [Bausch + Lomb unveils new ESCRS clinical data on enVista Aspire, LuxLife IOLs, ELIOS glaucoma procedure](https://longbridge.com/en/news/297903773.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**